
The Invesco Bloomberg Analyst Rating Improvers ETF, ticker symbol UPGD, is an investment vehicle designed to track the performance of the Bloomberg ANR Improvers Index. This exchange-traded fund typically commits at least 90% of its total holdings to the securities that comprise its underlying index. The index itself identifies the top 50 companies from the Bloomberg US Large Mid Universe that have shown the greatest improvement in analyst recommendations over the preceding six- and twelve-month periods. Both the index and the fund are rebalanced quarterly, specifically in March, June…
Is UPGD's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

I maintain the Hold rating on the Invesco Bloomberg Analyst Rating Improvers ETF. In contrast to 2025, UPGD has seen stronger performance this year, beating IVV in the first seven months, supported by its value and low volatility exposures and sector mix. Nevertheless, UPGD's performance edge has already disappeared in August, and I do not expect it to regain it in the remaining months of the year.

Invesco Bloomberg Analyst Rating Improvers ETF earns a 'sell' rating due to a flawed selection process that excludes large/mid-cap stocks rated "buy" or better. Unfortunately, this impacts a substantial number of stocks. For example, the average Wall Street rating for Russell 1000 Index stocks is 3.91/5, while "sell" ratings are in the extreme minority. Consequently, UPGD is constrained to holding stocks rated somewhere between neutral and buy, and this "average" selection process is reflected in UPGD's poor results since its March 2024 strategy change.

Invesco Bloomberg Analyst Rating Improvers ETF tracks the Bloomberg ANR Improvers Index that includes 50 analysts' darlings. Despite the alluring strategy, UPGD's performance has been underwhelming, as it has delivered only a single-digit total return this year and trailed IVV since March 2024. Its AUM has been fluctuating around $100 million this year, indicating rather muted investor interest. So UPGD's liquidity is not particularly ample, which is another weakness.

Tracking the Bloomberg ANR Improvers Index, UPGD offers exposure to 50 analysts' darlings. This is a high-turnover strategy, and significant quarterly changes in the sector and factor mix should not come as a surprise. At this point, UPGD is heavy in industrials, IT, and consumer staples.

After the strategy change in March 2024, UPGD tracks the Bloomberg ANR Improvers Index. The idea to capitalize on equity research analysts' darlings is appealing, but returns are less so. UPGD has underperformed IVV since the index change, with December being especially challenging, and its contrarian equity mix is to blame.